Breaking News

Tweet TWEET

BioReference Laboratories, Inc. Announces Earnings Date for Second Quarter Fiscal Year 2014

BioReference Laboratories, Inc. Announces Earnings Date for Second Quarter
Fiscal Year 2014

ELMWOOD PARK, N.J., May 29, 2014 (GLOBE NEWSWIRE) -- BioReference
Laboratories, Inc. (Nasdaq:BRLI) announced today it plans to issue earnings
results for the second quarter 2014 before the open of market trading on
Thursday, June 5, 2014. The Company's earnings conference call is to take
place the same day at 11:30 a.m. EDT.The call will be hosted by Marc D.
Grodman M.D., President and Chief Executive Officer.

The live Web cast will be available at the Company's corporate Web site,
www.bioreference.com, under Investor Relations, and through
www.streetevents.com.To listen to the live call please go to the Web site ten
minutes before the conference call is scheduled to begin. You will need to
register as well as download and install any necessary audio software. The Web
cast will be archived, on both Web sites, for 30 days following the call.

About BioReference Laboratories, Inc.

BRLI is a clinical testing laboratory offering testing, information and
related services to physician offices, clinics, hospitals, employers and
governmental units.We believe that we are the third largest full-service
laboratory in the United States.BRLI offers a comprehensive list of
laboratory testing services utilized by healthcare providers in the detection,
diagnosis, evaluation, monitoring and treatment of diseases.BRLI primarily
focuses on esoteric testing, molecular diagnostics, anatomical pathology,
women's health and correctional health care.

Statements included in this release that are not historical in nature, are
intended to be, and are hereby identified as "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995,
many of which are beyond our ability to control or predict. Forward-looking
statements may be identified by words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates," "will" or words of
similar meaning and include, but are not limited to, statements about the
expected future business and financial performance of Bio-Reference
Laboratories, Inc. and its subsidiaries. Statements looking forward in time
are included in this release pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Such statements involve
known and unknown risks and uncertainties that may cause the Company's actual
results in future periods to be materially different from any future
performance suggested herein. Risks and uncertainties that may affect the
future results of the company include, but are not limited to, adverse results
from future government investigations, lawsuits or private actions, including
the lawsuit described herein, the competitive environment, changes in
government regulations, changing relationships with customers, payers,
suppliers and strategic partners and other and other risks and uncertainties
detailed from time to time in our filings with the Securities and Exchange
Commission.We undertake no obligation to publicly update or review any
forward-looking information, whether as a result of new information, future
developments or otherwise.

                             www.bioreference.com

CONTACT: Tara Mackay
         Investor Relations Coordinator
         (201) 791-2600
         (201) 791-1941 (fax)
         tmackay@bioreference.com

Bio-Reference Laboratories, Inc. logo
 
Press spacebar to pause and continue. Press esc to stop.